|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 9/00 | (2006.01) |
| A61K 31/4045 | (2013.01) | ||
| A61K 31/4045 | (2006.01) | ||
| A61K 31/428 | (2013.01) | ||
| A61K 31/48 | (2013.01) | ||
| A61K 31/428 | (2006.01) | ||
| A61K 31/506 | (2013.01) | ||
| A61K 31/48 | (2006.01) | ||
| A61K 31/506 | (2006.01) | ||
| A61K 31/7034 | (2013.01) | ||
| A61K 31/70 | (2006.01) | ||
| A61K 31/7042 | (2013.01) | ||
| A61K 31/7034 | (2006.01) | ||
| A61K 31/7048 | (2013.01) | ||
| A61K 31/7042 | (2006.01) | ||
| A61K 31/7056 | (2013.01) | ||
| A61K 31/7048 | (2006.01) | ||
| A61K 31/70 | (2013.01) | ||
| A61K 31/7056 | (2006.01) | ||
| A61P 1/14 | (2018.01) | ||
| A61P 3/10 | (2006.01) | ||
| A61P 1/16 | (2018.01) | ||
| A61P 9/12 | (2006.01) | ||
| A61P 3/00 | (2018.01) | ||
| A61P 1/14 | (2006.01) | ||
| A61P 43/00 | (2018.01) | ||
| A61P 1/16 | (2006.01) | ||
| A61P 9/12 | (2018.01) | ||
| A61P 43/00 | (2006.01) | ||
| A61P 3/10 | (2018.01) |
| (11) | Number of the document | 3197429 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15774881.5 |
| Date of filing the European patent application | 2015-09-22 | |
| (97) | Date of publication of the European application | 2017-08-02 |
| (45) | Date of publication and mention of the grant of the patent | 2024-05-22 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2015/071637 |
| Date | 2015-09-22 |
| (87) | Number | WO 2016/046150 |
| Date | 2016-03-31 |
| (30) | Number | Date | Country code |
| 14186479 | 2014-09-25 | EP |
| (72) |
REICHE, Dania Birte , DE
RAHMEL, Daniela , DE
|
| (73) |
Boehringer Ingelheim Vetmedica GmbH ,
Binger Strasse 173, 55216 Ingelheim am Rhein,
DE
|
| (54) | COMBINATION TREATMENT OF SGLT2 INHIBITORS AND DOPAMINE AGONISTS FOR PREVENTING METABOLIC DISORDERS IN EQUINE ANIMALS |
| COMBINATION TREATMENT OF SGLT2 INHIBITORS AND DOPAMINE AGONISTS FOR PREVENTING METABOLIC DISORDERS IN EQUINE ANIMALS |